Close
  Indian J Med Microbiol
 

Figure 1: The study design based on American Urological Association guidelines where monotherapy with α-1a antagonist is recommended for prostate size <30 g and serum prostate-specific antigen value <1.5 ng/ml, while combination therapy with α-1a antagonist and 5 alpha reductase inhibitor is recommended for prostate size >30 g and serum prostate-specific antigen value >1.5 ng/ml

Figure 1: The study design based on American Urological Association guidelines where monotherapy with α-1a antagonist is recommended for prostate size <30 g and serum prostate-specific antigen value <1.5 ng/ml, while combination therapy with α-1a antagonist and 5 alpha reductase inhibitor is recommended for prostate size >30 g and serum prostate-specific antigen value >1.5 ng/ml